Hugendubel.info - Die B2B Online-Buchhandlung 

Merkliste
Die Merkliste ist leer.
Bitte warten - die Druckansicht der Seite wird vorbereitet.
Der Druckdialog öffnet sich, sobald die Seite vollständig geladen wurde.
Sollte die Druckvorschau unvollständig sein, bitte schliessen und "Erneut drucken" wählen.
E-BookPDF2 - DRM Adobe / Adobe Ebook ReaderE-Book
328 Seiten
Englisch
John Wiley & Sonserschienen am12.07.20195. Auflage
The Union for International Cancer Control's (UICC) TNM classification system is the most widely used cancer classification and staging system in the world. It is used to describe the anatomical extent of disease and it is essential to patient care, research and cancer control.

This fifth edition of the TNM Supplement: A Commentary of Uniform Use offers practitioners a wealth of material intended to complement the system's day-to-day use. The volume features:
Updated definitions of terms used in cancer staging.
New sections on carcinomas of the thymus, sarcomas of the spine and pelvis and soft tissue sarcomas of the head and neck, and comprehensive updates to the head and neck carcinomas, carcinomas of the lung and neuroendocrine tumours sections.
Frequently asked questions from the UICC helpdesk.


The Supplement may be treated as a companion text to the recent eighth edition of the TNM Classification of Malignant Tumours (978-1-119-26357-9), supporting the correct and uniform application of the TNM classification system. The TNM Supplement can also be utilised as a standalone book, providing explanations and examples to answer many questions that arise during the daily use of the TNM cancer classification and staging system, particularly in unusual cases.



Christian Wittekind, MD; Professor of Pathology, Chairman Institute of Pathology, University of Leipzig, Germany.

James D Brierley, BSc, MB, FRCP, FRCR, FRCPC; Professor, Department of Radiation Oncology, Princess Margaret Cancer Centre / University of Toronto, Toronto, Ontario, Canada.

Anne W. M. Lee, MD; Clinical Professor, Department of Clinical Oncology, The University of Hong Kong, Hong Kong, China.

Elisabeth van Eycken, MD; Director, Belgium Cancer Registry, Brussels, Belgium.
mehr
Verfügbare Formate
BuchKartoniert, Paperback
EUR50,00
TaschenbuchKartoniert, Paperback
EUR78,00
E-BookPDF2 - DRM Adobe / Adobe Ebook ReaderE-Book
EUR43,99
E-BookEPUB2 - DRM Adobe / EPUBE-Book
EUR43,99

Produkt

KlappentextThe Union for International Cancer Control's (UICC) TNM classification system is the most widely used cancer classification and staging system in the world. It is used to describe the anatomical extent of disease and it is essential to patient care, research and cancer control.

This fifth edition of the TNM Supplement: A Commentary of Uniform Use offers practitioners a wealth of material intended to complement the system's day-to-day use. The volume features:
Updated definitions of terms used in cancer staging.
New sections on carcinomas of the thymus, sarcomas of the spine and pelvis and soft tissue sarcomas of the head and neck, and comprehensive updates to the head and neck carcinomas, carcinomas of the lung and neuroendocrine tumours sections.
Frequently asked questions from the UICC helpdesk.


The Supplement may be treated as a companion text to the recent eighth edition of the TNM Classification of Malignant Tumours (978-1-119-26357-9), supporting the correct and uniform application of the TNM classification system. The TNM Supplement can also be utilised as a standalone book, providing explanations and examples to answer many questions that arise during the daily use of the TNM cancer classification and staging system, particularly in unusual cases.



Christian Wittekind, MD; Professor of Pathology, Chairman Institute of Pathology, University of Leipzig, Germany.

James D Brierley, BSc, MB, FRCP, FRCR, FRCPC; Professor, Department of Radiation Oncology, Princess Margaret Cancer Centre / University of Toronto, Toronto, Ontario, Canada.

Anne W. M. Lee, MD; Clinical Professor, Department of Clinical Oncology, The University of Hong Kong, Hong Kong, China.

Elisabeth van Eycken, MD; Director, Belgium Cancer Registry, Brussels, Belgium.
Details
Weitere ISBN/GTIN9781119263944
ProduktartE-Book
EinbandartE-Book
FormatPDF
FormatFormat mit automatischem Seitenumbruch (reflowable)
Erscheinungsjahr2019
Erscheinungsdatum12.07.2019
Auflage5. Auflage
ReiheUICC
Seiten328 Seiten
SpracheEnglisch
Dateigrösse4827 Kbytes
Artikel-Nr.4739953
Rubriken
Genre9201

Inhalt/Kritik

Inhaltsverzeichnis
1;TITLE PAGE;5
2;COPYRIGHT PAGE;6
3;CONTENTS;7
4;PREFACE;10
5;ORGANIZATIONS ASSOCIATED WITH THE TNM SYSTEM;15
6;NATIONAL COMMITTEES;15
7;ACKNOWLEDGEMENTS;17
8;ABBREVIATIONS;18
9;CHAPTER 1 EXPLANATORY NOTES - GENERAL;19
9.1;The General Rules of the TNM System;19
9.1.1;General Rule No. 1;19
9.1.2;General Rule No. 2 (Table 1.1);19
9.1.3;General Rule No. 3;21
9.1.4;General Rule No. 4;23
9.1.5;General Rule No. 5;23
9.2;The TNM Clinical and Pathological Classifications;25
9.2.1;T/pT Classification;25
9.2.2;Regional Lymph Nodes;26
9.2.3;N/pN Classification;27
9.2.4;Sentinel Lymph Node;29
9.2.5;M Classification;29
9.2.6;Who Is Responsible for TNM Coding?;30
9.2.7;The Significance of X;30
9.2.8;Stages;31
9.3;Residual Tumour (R) Classification;33
9.3.1;Definitions of Completeness of Resection;37
9.4;Additional Descriptors;38
9.4.1;m Symbol;38
9.4.2;y Symbol - Classifying Treated Tumours;38
9.4.3;Recurrent Tumour, r Symbol;39
9.4.4;a Symbol;41
9.5;Optional Descriptors;42
9.5.1;Lymphatic Invasion (L Classification);42
9.5.2;Venous Invasion (V Classification);42
9.5.3;Pn - Perineural Invasion;42
9.5.4;Symbols for Describing Methods of Staging;43
9.6;Unknown Primary;43
9.7;Staging of Tumours for Which No TNM Classification is Provided;43
9.8;Histopathological Grading;44
9.9;References;46
10;CHAPTER 2 EXPLANATORY NOTES - SPECIFIC ANATOMICAL SITES;52
10.1;Head and Neck Tumours;52
10.1.1;General;52
10.1.2;Definition of Masticator Space;53
10.1.3;Definition of the Paraglottic Space;53
10.1.4;Extension to Adjacent Sites;53
10.1.5;Regional Lymph Nodes;54
10.1.6;N Classification;58
10.1.7;T Classification;59
10.1.8;Lip and Oral Cavity;59
10.1.9;Lip;59
10.1.10;Oral Cavity;60
10.1.11;Pharynx;61
10.1.12;Nasopharynx;63
10.1.13;Hypopharynx;64
10.1.14;Larynx;65
10.1.15;Anatomical Definitions;66
10.1.16;Pathological Criteria of Impaired Vocal Cord Mobility or Vocal Cord Fixation;67
10.1.17;Nasal Cavity and Paranasal Sinuses;67
10.1.18;Unknown Primary - Cervical Lymph Nodes;68
10.1.19;Malignant Melanoma of the Upper Aerodigestive Tract;69
10.1.20;Salivary Glands;70
10.1.21;Thyroid;70
10.2;Digestive System Tumours;72
10.2.1;Rules for Classification;72
10.2.2;Oesophagus;73
10.2.3;Regional Lymph Nodes;74
10.2.4;Stages and Prognostic Groups;76
10.2.5;Stomach;80
10.2.6;Anatomical Definitions of Lymph Node Stations [37-39];80
10.2.7;Small Intestine;84
10.2.8;Appendix;85
10.2.9;Colon and Rectum;87
10.2.10;Anal Canal and Perianal Skin;91
10.2.11;Liver - Hepatocellular Carcinoma;92
10.2.12;Liver - Intrahepatic Bile Ducts;93
10.2.13;Gallbladder;94
10.2.14;Extrahepatic Bile Ducts;95
10.2.15;1) Perihilar Extrahepatic Bile Ducts;95
10.2.16;2) Distal Extrahepatic Bile Ducts;96
10.2.17;Ampulla of Vater;97
10.2.18;Pancreas;97
10.2.19;Neuroendocrine Tumours;98
10.2.20;Neuroendocrine Neoplasms of the Stomach;99
10.2.21;Neuroendocrine Neoplasms of the Duodenum and Ampulla of Vater;100
10.2.22;Neuroendocrine Neoplasms of the Jejunum and Ileum;100
10.2.23;Neuroendocrine Neoplasms of the Appendix;101
10.2.24;Neuroendocrine Neoplasms of the Colon and Rectum;101
10.2.25;Neuroendocrine Neoplasms of the Pancreas;102
10.3;Lung, Pleural and Thymic Tumours;103
10.3.1;Lung;103
10.3.2;Pleural Mesothelioma;119
10.3.3;Thymic Tumours;120
10.4;Bone Tumours;122
10.5;Soft Tissue Tumours;124
10.5.1;Histological Types of Tumours;124
10.6;Gastrointestinal Stromal Tumour (GIST);126
10.7;Skin Tumours;128
10.7.1;Skin Carcinoma of Head and Neck;130
10.7.2;Eyelid Carcinoma;131
10.7.3;Malignant Melanoma of Skin;131
10.7.4;Merkel Cell Carcinoma of Skin;135
10.8;Breast Tumours;136
10.9;Gynaecological Tumours;140
10.9.1;Vulva;140
10.9.2;Vagina;141
10.9.3;Cervix Uteri;141
10.9.4;Uterus - Endometrium;143
10.9.5;Uterine Sarcomas;145
10.9.6;Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma;146
10.9.7;Gestational Trophoblastic Tumours;148
10.10;Urological Tumours;149
10.10.1;Penis;149
10.10.2;Prostate;150
10.10.3;Testis;153
10.10.4;Kidney;155
10.10.5;Renal Pelvis and Ureter;156
10.10.6;Urinary Bladder;157
10.10.7;Urethra;159
10.10.8;Adrenal Cortex Tumours;160
10.11;Ophthalmic Tumours;160
10.11.1;Carcinoma of the Conjunctiva;160
10.11.2;Malignant Melanoma of Conjunctiva;161
10.11.3;Malignant Melanoma of Uvea;162
10.11.4;Retinoblastoma;164
10.11.5;Sarcoma of Orbit;166
10.11.6;Carcinoma of the Lacrimal Gland;166
10.12;Hodgkin and Non-Hodgkin Lymphomas;167
10.12.1;Non-Hodgkin Lymphomas;168
10.13;References;168
11;CHAPTER 3 SITE-SPECIFIC REQUIREMENTS FOR pT AND pN;175
11.1;Introduction;175
11.2;Head and Neck Tumours;178
11.3;Digestive System Tumours;184
11.3.1;pT - Primary Tumour;184
11.3.2;Well-Differentiated Neuroendocrine Tumours of the Gastrointestinal Tract;187
11.3.3;pN - Regional Lymph Nodes;188
11.4;Lung and Pleural Tumours;191
11.4.1;Thymic Tumours;192
11.5;Tumours of Bone and Soft Tissues;194
11.6;Skin Tumours;197
11.7;Breast Tumours;201
11.8;Gynaecological Tumours;203
11.9;Urological Tumours;206
11.10;Adrenal Cortex Tumours;210
11.11;Ophthalmic Tumours;211
11.12;Hodgkin and Non?Hodgkin Lymphomas;213
11.12.1;Clinical Staging (cS);213
11.13;References;214
12;CHAPTER 4 NEW TNM CLASSIFICATIONS RECOMMENDED FOR TESTING AND OTHER CLASSIFICATIONS;216
12.1;Introduction;216
12.2;General;216
12.3;Specific;216
12.4;Non Upper Aerodigestive Tract Mucosal Melanoma;217
12.4.1;Regional Lymph Nodes;217
12.5;Primary Liver Carcinoma of Infants and Children/Hepatoblastoma;218
12.5.1;Rules for Classification;218
12.5.2;Regional Lymph Nodes;219
12.6;Primary Cutaneous Lymphomas;220
12.7;Cutaneous T-Cell Lymphomas;220
12.7.1;Rules for Classification;220
12.7.2;Anatomical Sites;220
12.7.3;Regional Lymph Nodes;220
12.8;Primary Cutaneous Lymphomas;221
12.8.1;Introduction;221
12.8.2;T - Primary Tumour;221
12.8.3;N - N Classification;221
12.8.4;M - M Classification;222
12.9;Histopathologic Staging of Lymph Nodes in Mycosis Fungoides and Sézary Syndrome;222
12.10;Primary Cutaneous B-Cell/T-Cell Lymphoma (Non-MF/SS Lymphoma);224
12.10.1;T - Primary Tumour;224
12.10.2;N - Regional Lymph Nodes;224
12.10.3;M - Distant Metastasis;224
12.10.4;Prognostic Groups;224
12.10.5;Definitions (International League of Dermatological Societies 1987 [6]);225
12.11;Multiple Myeloma;225
12.11.1;International Staging System;225
12.12;Leukaemia;226
13;CHAPTER 5 OPTIONAL PROPOSALS FOR TESTING NEW SUBCATEGORIES OF TNM;227
13.1;All Tumour Sites;228
13.1.1;Fixation of Lymph Nodes;228
13.2;Head and Neck Tumours;228
13.2.1;Thyroid Gland;228
13.3;Digestive System Tumours;229
13.3.1;Oesophagus;229
13.3.2;Colon;230
13.3.3;Rectum;230
13.4;Lung Tumours;231
13.5;Breast Tumours (ICD-0-3 C50);232
13.5.1;Current TNM Classification;232
13.5.2;New Proposed Classification;233
13.5.3;Current TNM Classification;233
13.5.4;New Proposed Classification;233
13.6;Gynaecological Tumours;233
13.6.1;Cervix Uteri (ICD?O C53);233
13.7;Urological Tumours;233
13.7.1;Prostate;233
14;CHAPTER 6 FREQUENTLY ASKED QUESTIONS;236
14.1;General Questions;236
14.1.1;AJCC and UICC;236
14.1.2;Date of Implementation;236
14.1.3;In Situ Carcinoma;237
14.1.4;Pathological Versus Clinical TNM;237
14.1.5;When in Doubt;238
14.1.6;R Classification;238
14.1.7;R Classification and Tis;239
14.1.8;Positive Cytology;239
14.1.9;T0 and TX;240
14.1.10;Synchronous Tumours;240
14.1.11;Simultaneous Tumours;241
14.1.12;Single Tumour Cells and Micrometastasis in Lymph Nodes;242
14.1.13;Number of Lymph Nodes;243
14.1.14;Pathological Assessment of Distant Metastasis;243
14.1.15;Classification of Brain Tumours;243
14.1.16;Tumours of the Frontal and Sphenoidal Sinuses;244
14.1.17;Carcinoma of the Trachea;244
14.1.18;Carcinoma of the Urachus;244
14.1.19;Tumour Spillage;244
14.1.20;Tumour Cells in Lymphatics;244
14.1.21;Direct Spread;245
14.1.22;N Versus M;245
14.1.23;Recurrent Tumour;245
14.1.24;Unknown Primary;246
14.1.25;Sentinel Lymph Node;247
14.2;Site-Specific Questions;247
14.2.1;Oral Cavity;247
14.2.2;Oropharynx;249
14.2.3;Hypopharynx;250
14.2.4;Larynx;250
14.2.5;Unknown Primary - Cervical Nodes;251
14.2.6;Thyroid Gland;252
14.2.7;Oesophagus;253
14.2.8;Stomach;255
14.2.9;Colon and Rectum;257
14.2.10;Anal Canal;264
14.2.11;Liver (Hepatocellular Carcinoma) - Intrahepatic Bile Ducts;264
14.2.12;Gallbladder;265
14.2.13;Bile Ducts - Perihilar Bile Ducts;266
14.2.14;Bile Ducts - Distal Extrahepatic Bile Duct;266
14.2.15;Ampulla of Vater;268
14.2.16;Pancreatic Tumours;268
14.2.17;Neuroendocrine Tumours of the Gastrointestinal Tract;269
14.2.18;Lung Tumours;271
14.2.19;Skin Tumours;281
14.2.20;Breast Tumours;283
14.2.21;Gynaecological Tumours;291
14.2.22;Urological Tumours;299
14.3;References;307
15;INDEX;309
16;SUPPLEMENTAL IMAGES;328
17;EULA;331
mehr

Autor